ATE396745T1 - Complex enthaltend modafinil und cyclodextrin - Google Patents

Complex enthaltend modafinil und cyclodextrin

Info

Publication number
ATE396745T1
ATE396745T1 AT01994302T AT01994302T ATE396745T1 AT E396745 T1 ATE396745 T1 AT E396745T1 AT 01994302 T AT01994302 T AT 01994302T AT 01994302 T AT01994302 T AT 01994302T AT E396745 T1 ATE396745 T1 AT E396745T1
Authority
AT
Austria
Prior art keywords
cyclodextrin
complex containing
containing modafinil
modafinil
modafinil compound
Prior art date
Application number
AT01994302T
Other languages
English (en)
Inventor
Martin Jacobs
Piyush Patel
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE396745T1 publication Critical patent/ATE396745T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AT01994302T 2000-12-19 2001-12-19 Complex enthaltend modafinil und cyclodextrin ATE396745T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25668100P 2000-12-19 2000-12-19
US10/023,441 US7141555B2 (en) 2000-12-19 2001-12-18 Modafinil compound and cyclodextrin mixtures

Publications (1)

Publication Number Publication Date
ATE396745T1 true ATE396745T1 (de) 2008-06-15

Family

ID=26697157

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994302T ATE396745T1 (de) 2000-12-19 2001-12-19 Complex enthaltend modafinil und cyclodextrin

Country Status (23)

Country Link
US (1) US7141555B2 (de)
EP (1) EP1368063B1 (de)
JP (1) JP4094428B2 (de)
KR (1) KR20040012696A (de)
CN (1) CN100384477C (de)
AT (1) ATE396745T1 (de)
AU (1) AU2002246711B2 (de)
BG (1) BG108009A (de)
BR (1) BR0116698A (de)
CA (1) CA2432126C (de)
CZ (1) CZ20031878A3 (de)
DE (1) DE60134274D1 (de)
EA (1) EA200300705A1 (de)
ES (1) ES2305128T3 (de)
HK (1) HK1059055A1 (de)
HU (1) HUP0401592A2 (de)
IL (1) IL156470A0 (de)
MX (1) MXPA03005505A (de)
NO (1) NO20032788L (de)
NZ (1) NZ526780A (de)
PL (1) PL362474A1 (de)
SK (1) SK9012003A3 (de)
WO (1) WO2002056915A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224006A1 (en) 2002-03-01 2003-12-04 Zaworotko Michael J. Multiple-component solid phases containing at least one active pharmaceutical ingredient
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
JP2004250390A (ja) * 2003-02-21 2004-09-09 Taisho Pharmaceut Co Ltd 鉄化合物配合内服液剤
EP1608343B1 (de) 2003-03-28 2016-04-27 Ares Trading S.A. Cladribin-formulierungen zur verbesserten oralen und transmukosalen abgabe
DK2272503T3 (da) * 2003-03-28 2013-05-21 Ares Trading Sa Orale formuleringer af cladribin
NZ545133A (en) * 2003-09-04 2009-12-24 Cephalon Inc Modafinil compositions
US7566805B2 (en) 2003-09-04 2009-07-28 Cephalon, Inc. Modafinil compositions
BRPI0413777A (pt) * 2003-09-04 2006-11-07 Cephalon Inc composições de modafinil
AR046410A1 (es) 2003-09-18 2005-12-07 Cephalon Inc Composiciones farmaceuticas para la liberacion modificada de modafinilo
US20090018202A1 (en) 2004-02-06 2009-01-15 Cephalon, Inc. Modafinil compositions
WO2005117911A2 (en) * 2004-05-06 2005-12-15 Cydex, Inc. Taste-masked formulations containing sertraline and sulfoalkyl ether cyclodextrin
US20060024370A1 (en) * 2004-07-29 2006-02-02 Cephalon France Modafinil oral lyophilizate
CN100503647C (zh) * 2005-11-02 2009-06-24 南京师范大学 羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
EP2043623A4 (de) * 2006-07-12 2013-03-20 Elan Pharma Int Ltd Nanopartikelformulierungen von modafinil
JP2009091309A (ja) * 2007-10-10 2009-04-30 Japan Organo Co Ltd バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品
US10463677B2 (en) 2008-11-07 2019-11-05 Cydex Pharmaceuticals, Inc. Composition containing sulfoalkyl ether cyclodextrin and latanoprost
KR101026864B1 (ko) * 2009-10-08 2011-04-12 (주)송호바이오메드 고 수용성 2―하이드록시프로필―베타사이클로덱스트린을 유효성분으로 함유하는 비만 질환 예방 및 치료용 조성물
CN102711774B (zh) * 2009-10-08 2014-09-24 株式会社松湖生物医学 含有高水溶性2-羟丙基-β-环糊精作为有效成分的肥胖疾病预防及治疗用组合物
NZ608239A (en) 2010-09-13 2015-05-29 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
US9474715B2 (en) 2011-11-30 2016-10-25 Andreas Voigt Polymeric drug-delivery material, method for manufacturing thereof and method for delivery of a drug-delivery composition
US9364549B2 (en) 2011-11-30 2016-06-14 Andreas Voigt Hydrophobic drug-delivery material, method for manufacturing thereof and methods for delivery of a drug-delivery composition
US9616068B2 (en) 2014-10-27 2017-04-11 Pohela LLC Animal training using cognitive enhancement
KR101719987B1 (ko) 2015-08-03 2017-03-27 (주)상전정공 화물차량의 잠금장치
US9855228B1 (en) 2016-12-14 2018-01-02 Taho Pharmaceuticals Ltd. Oral solution comprising atomoxetine hydrochloride and methods thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5835968B2 (ja) * 1974-02-25 1983-08-05 帝人株式会社 サイクロデキストリン包接化合物の製造法
GB1584462A (en) 1977-03-31 1981-02-11 Lafon Labor N-diaryl-malonamide and diarylmethyl-sulphinyl-acetamide derivatives and pharmaceutical compositions containing them
JPS5920230A (ja) 1982-07-19 1984-02-01 チバ−ガイギ−・アクチエンゲゼルシヤフト ピルプロフエン含有薬剤
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
FR2593809B1 (fr) * 1986-01-31 1988-07-22 Lafon Labor Benzhydrylsulfinylacetamide, procede de preparation et utilisation en therapeutique
JPS62281855A (ja) * 1986-05-29 1987-12-07 Daikin Ind Ltd ビタミン,ビタミン誘導体,またはホルモンを含有する包接化合物
GB8813682D0 (en) * 1988-06-09 1988-07-13 Reckitt & Colmann Prod Ltd Pharmaceutical compositions
JPH035438A (ja) * 1989-05-31 1991-01-11 Kaken Pharmaceut Co Ltd フルルビプロフェン包接化合物およびこの包接化合物を用いる消炎鎮痛剤
SE8902235D0 (sv) * 1989-06-20 1989-06-20 Haessle Ab Novel cyclodextrin inclusion complexes
FR2663225B1 (fr) 1990-06-14 1994-11-04 Lafon Labor Nouvelle utilisation du modafinil.
US5024997A (en) 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
FR2684875B1 (fr) * 1991-12-13 1995-05-24 Lafon Labor Utilisation du modafinil pour la fabrication d'un medicament ayant un effet anti-ischemique.
FR2702968B1 (fr) 1993-03-23 1995-06-23 Lafon Labor Procédé de préparation de particules renfermant un ingrédient actif par extrusion et lyophilisation .
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
US5866162A (en) 1993-08-10 1999-02-02 Smithkline Beecham P.L.C. Pharmaceutical composition containing a drug/β-cyclodextrin complex in combination with an acid-base couple
US5618845A (en) 1994-10-06 1997-04-08 Cephalon, Inc. Acetamide derivative having defined particle size
US6077871A (en) 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
US6200968B1 (en) 1998-08-06 2001-03-13 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
US6346548B1 (en) * 1999-08-16 2002-02-12 Cephalon, Inc. Compositions including modafinil for treatment of attention deficit hyperactivity disorder and multiple sclerosis fatigue
US6455588B1 (en) * 1999-08-20 2002-09-24 Cephalon, Inc. Compositions including modafinil for treatment of eating disorders and for appetite stimulation

Also Published As

Publication number Publication date
BR0116698A (pt) 2003-10-21
CA2432126A1 (en) 2002-07-25
BG108009A (en) 2004-09-30
ES2305128T3 (es) 2008-11-01
CZ20031878A3 (cs) 2004-10-13
IL156470A0 (en) 2004-01-04
PL362474A1 (en) 2004-11-02
HUP0401592A2 (hu) 2004-11-29
CA2432126C (en) 2011-03-08
NO20032788L (no) 2003-07-07
MXPA03005505A (es) 2003-10-06
EA200300705A1 (ru) 2003-12-25
KR20040012696A (ko) 2004-02-11
JP2004525104A (ja) 2004-08-19
AU2002246711B2 (en) 2006-12-14
WO2002056915A2 (en) 2002-07-25
JP4094428B2 (ja) 2008-06-04
CN100384477C (zh) 2008-04-30
SK9012003A3 (en) 2003-12-02
HK1059055A1 (en) 2004-06-18
NO20032788D0 (no) 2003-06-18
WO2002056915A3 (en) 2003-01-03
EP1368063B1 (de) 2008-05-28
CN1486196A (zh) 2004-03-31
US20020160982A1 (en) 2002-10-31
DE60134274D1 (en) 2008-07-10
US7141555B2 (en) 2006-11-28
EP1368063A2 (de) 2003-12-10
NZ526780A (en) 2005-07-29

Similar Documents

Publication Publication Date Title
ATE396745T1 (de) Complex enthaltend modafinil und cyclodextrin
CY1110061T1 (el) Συνθεσεις περιλαμβανοντας ενωσεις μοδαφινιλης
ATE376996T1 (de) Antibakterielle mittel
CY1112946T1 (el) 4-υδροξυβενζομορφανια
NO20030929L (no) Guanidinobenzamider som MC4-R agonister
NO20025450L (no) Ny farmasöytisk sammensetning
ATE372372T1 (de) Zusammensetzungen enthaltend cyclodextrin
ATE453391T1 (de) Östrogene mittel enthaltende arzneizusammensetzungen
DE60106954D1 (de) Resorcin-derivate
CY1106056T1 (el) Παραγωγα 2-αμινο-2-αλκυλ-5-επτενοϊκου και επτυνοϊκου οξεος χρησιμα σαν αναστολεις συνθασης νιτρικου οξειδιου
CY1110258T1 (el) Υποκατεστημενα παραγωγα c-κυκλοεξυλομεθυλαμινης
ATE478662T1 (de) Arzneilösungen enthaltend modafinilverbindungen
DK1322654T3 (da) Platinkomplekser som antitumormidler
DE60304223D1 (de) Herstellung von metallamid-komplexen
ATE325135T1 (de) 2-alkylierte cyclodextrinderivate : umkehrungsmittel von medikament-induzierter neuromuskulärer blockierung
NO20014752L (no) Taxanpreparater med forbedret opplöselighet
NO20040702L (no) Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
TR200402070T4 (tr) Siklobüten-dion türevleri ve bunların damar sertliği tedavisinde kullanımı
AR038560A1 (es) Una composicion antitranspirante/ desodorante
NO20014753L (no) C(10)-karbonatsubstituerte taxaner som antitumormidler
NO20023697D0 (no) Cykliske heksapeptidderivater
DE602004013011D1 (de) Haarbehandlungszusammensetzungen
TR201910060T4 (tr) SYN3 bileşimleri ve yöntemleri.
ATE287708T1 (de) 1-amino-alkylcyclohexanederivate als trypanocide mittel
DE50310743D1 (de) Wässrige formulierungen von (2-hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4- trifluorbutan-1-sulfonat

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties